Article · Wikipedia archive · Last revised Jun 3, 2026

Enitociclib

Enitociclib is an experimental drug that is being investigated for the treatment of cancer. It is an inhibitor of the kinase CDK9.

Last revised
Jun 3, 2026
Read time
≈ 1 min
Length
125 w
Citations
3
Source
Enitociclib
Identifiers
  • 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-N-[4-[(methylsulfonimidoyl)methyl]pyridin-2-yl]pyridin-2-amine
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
ChEBI
ChEMBL
Chemical and physical data
FormulaC19H18F2N4O2S
Molar mass404.44 g·mol−1
3D model (JSmol)
  • COC1=C(C=CC(=C1)F)C2=CC(=NC=C2F)NC3=NC=CC(=C3)C[S@@](=N)(=O)C
  • InChI=nChI=1S/C19H18F2N4O2S/c1-27-17-8-13(20)3-4-14(17)15-9-19(24-10-16(15)21)25-18-7-12(5-6-23-18)11-28(2,22)26/h3-10,22H,11H2,1-2H3,(H,23,24,25)/t28-/m0/s1
  • Key:YZCUMZWULWOUMD-NDEPHWFRSA-N

Enitociclib is an experimental drug that is being investigated for the treatment of cancer.1 It is an inhibitor of the kinase CDK9.23

References

References

  1. "Enitociclib - Vincerx Pharma". AdisInsight. Springer Nature Switzerland AG.
  2. Morillo D, Vega G, Moreno V (August 2023). "CDK9 INHIBITORS: a promising combination partner in the treatment of hematological malignancies". Oncotarget. 14: 749–752. doi:10.18632/oncotarget.28473. PMC 10408673. PMID 37552223.
  3. Frigault MM, Mithal A, Wong H, Stelte-Ludwig B, Mandava V, Huang X, et al. (November 2023). "Enitociclib, a Selective CDK9 Inhibitor, Induces Complete Regression of MYC+ Lymphoma by Downregulation of RNA Polymerase II Mediated Transcription". Cancer Research Communications. 3 (11): 2268–2279. doi:10.1158/2767-9764.CRC-23-0219. PMC 10634346. PMID 37882668.